Related Experiment Video
Updated: Aug 29, 2026

Global and Current Research Trends of Single-Cell Sequencing in Cancer: A Bibliometric and Visualization Study
Published on: April 18, 2025
Cancer Research and Development in South Korea, 2006-2024: A Text-Mining Analysis of National Science & Technology
Kang Seo1, So-Yoon Lee1, Soohyun Yu1
1Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Korea.
Purpose:
To characterize trends and structural patterns in government-funded cancer research and development (R&D) in South Korea using National Science & Technology Information Service (NTIS) records.
Materials And Methods:
We analyzed all NTIS projects during 2006-2024 (n=519,618), extracted via the NTIS OpenAPI. A bilingual regular-expression lexicon applied to Korean and English titles and keywords classified projects as definite (C2), possibly (C1), or unrelated (C0) to cancer, validated by two independent physicians on stratified samples. Outcomes included annual cancer-related project counts and funding, research-stage composition, and keyword dynamics.
Results:
The lexicon identified 18,833 definite and 381 possible cancer-related projects, with high validated accuracy (κ=0.997). Cancer-related projects rose from 905 in 2006 (2.85% of NTIS projects) to a peak of 4,008 in 2021 (5.42%) and then plateaued (3,753 in 2023). In 2024, amid a government-wide R&D reduction, counts declined to 3,386 (5.67%), though cancer-related R&D was relatively protected as its NTIS share rose. Funding peaked at approximately 673 billion KRW in 2023 (1.9%-3.3% of annual government R&D). Basic research accounted for 71.7% of projects, whereas funding was more evenly distributed (basic 51.4%, development 23.0%, applied 17.5%). Keywords shifted from anticancer drugs and metastasis toward microenvironment, biomarkers, immunotherapy, liquid biopsy, organoids, and artificial intelligence.
Conclusion:
Government-funded cancer R&D in South Korea expanded through 2021 and was subsequently sustained-including relative protection during the 2024 government-wide R&D reduction-while retaining a basic-research backbone and shifting toward precision- and data-intensive oncology. NTIS-based monitoring may help guide strategic allocation of public cancer R&D.
More Related Videos
09:20Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts
Published on: June 26, 2018
12:55Assay for Phosphorylation and Microtubule Binding Along with Localization of Tau Protein in Colorectal Cancer Cells
Published on: October 10, 2017
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Cancer
Cancer Survival Analysis
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...